Case Report
Copyright ©The Author(s) 2022.
World J Clin Cases. Feb 6, 2022; 10(4): 1291-1295
Published online Feb 6, 2022. doi: 10.12998/wjcc.v10.i4.1291
Figure 1
Figure 1 Course of ophthalmoscopy examinations. A: Image showing multifocal, creamy yellow, subretinal infiltrates during the first clinical visit; B: Image showing the spread of the creamy yellow, subretinal infiltrates toward the mid-periphery of the fundus. The image was taken 4 mo after the first clinical visit; C: Subretinal infiltrates appear to be markedly decreased after six cycles of systemic chemotherapy.
Figure 2
Figure 2 Findings of brain magnetic resonance imaging. A: Image showing no evidence of space-occupying intracranial or diffusion-restricted lesions. The image was taken at the first clinical visit; B: Image showing an irregular contrast-enhancing lesion, measuring approximately 3.8 cm × 3.8 cm in size, with diffusion restriction in the left cerebellum. The image was taken 4 mon after the first clinical visit; C: Image showing no evidence of abnormal contrast-enhancing lesion in the cerebellum after six cycles of systemic chemotherapy.
Figure 3
Figure 3 Representative microscopic images of diffuse large B-cell lymphoma in the brain. A: Infiltration of large, atypical cells with prominent nucleoli around the granular layer of the cerebellum (hematoxylin and eosin stain, magnification: 200 ×); B: Infiltration of large, atypical cells with prominent nucleoli around the granular layer of the cerebellum (hematoxylin and eosin stain, magnification: 400 ×); C: Tumor cells show strong positivity for the B-cell surface marker CD20 on immunohistochemistry (Immunohistochemical stain, magnification: 200 ×).